articleTop 1% cited

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial

Arthritis & Rheumatism · 2005 · Vol. 52(10) · pp. 3279–3289

Philip J. Mease✉(Swedish Medical Center)Dafna D. Gladman(University of Toronto)Christopher T. Ritchlin(University of Rochester)Eric Ruderman(Northwestern University)Serge Steinfeld(Erasmus Hospital)Ernest Choy(King's College London)John T. Sharp(University of Washington)P A Ory(Southwest Washington Medical Center)Renee Perdok(Abbott Fund)Mark Weinberg(Abbott Fund)

View via DOI Publisher page

Abstract

Adalimumab significantly improved joint and skin manifestations, inhibited structural changes on radiographs, lessened disability due to joint damage, and improved quality of life in patients with moderately to severely active PsA.

Autoimmune and Inflammatory Disorders Research Spondyloarthritis Studies and Treatments Rheumatoid Arthritis Research and TherapiesAdalimumabMedicinePsoriatic arthritisPlaceboPsoriasisInternal medicineDermatology Life Quality IndexRheumatologyPsoriasis Area and Severity IndexQuality of life (healthcare)

MeSH terms

AdalimumabAdultAntibodies, MonoclonalDisability EvaluationDouble-Blind MethodFemaleHumansInjections, SubcutaneousJointsMaleMiddle AgedPlacebosQuality of LifeSeverity of Illness IndexSkin

Citations

902

FWCI

25.98

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009